# Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD

> **NCT02161575** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 103 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT02161575
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-28
- **Primary completion:** 2017-09-14
- **Final completion:** 2017-09-14
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2019-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02161575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02161575, "Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02161575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*